Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

ASH 2024 Insights: De-Escalated PTCy & Ruxolitinib for GVHD Prophyla…

2024 ASH Annual Meeting Insights Hub

S. Abedin

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Making Sense of 1L Treatment Options in MCL

SOHO Brazil 2024

T. Phillips

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong

Standards of Care and Future Directions in MCL

Martin Dreyling

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

University of Colorado Division of Hematology

M. Kamdar

When Not to Watch and Wait: Emerging Strategies in the Treatment of …

Indy Hematology Review

M. Williams

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

The Evolving Landscape of cGVHD Treatment Options

Giuseppe Francesco Milone

Current and Future Therapeutic Approaches to cGVHD

Kirk Schultz

CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD

Najla El-Jurdi

CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD

Robert Zeiser